CDC42EP3 Antibody

What is CDC42EP3 and what cellular functions does it regulate?

CDC42EP3 (CDC42 effector protein 3), also known as BORG2, CEP3, and UB1, is a member of the BORG family of CDC42 effector proteins. It functions primarily as a cytoskeletal regulator by:

• Binding to both F-actin and septin networks

• Localizing at the interface between F-actin fibers and SEPT2 filaments

• Stabilizing cytoskeletal networks particularly in cancer-associated fibroblasts (CAFs)

• Mediating pseudopodia formation during cell shape changes

CDC42EP3 contains a CRIB (CDC42/Rac interactive binding) domain that allows it to act as an effector of CDC42 function. It plays critical roles in cell shape regulation, migration, and tumor progression .

How do I select the appropriate CDC42EP3 antibody for my experimental needs?

When selecting a CDC42EP3 antibody, consider these methodological factors:

Always verify species reactivity (human, mouse, rat) and validate the antibody in your specific experimental system by including appropriate positive and negative controls .

What are the expected molecular weight and cellular localization patterns for CDC42EP3?

While the calculated molecular weight of CDC42EP3 is approximately 27-28 kDa, the observed molecular weight in Western blot is often around 37 kDa . This disparity can be attributed to post-translational modifications.

For cellular localization:

• In normal conditions: Primarily cytoplasmic with filamentous structures

• When activated: Forms distinct filamentous patterns associated with the cytoskeleton

• Subcellular regions: Endomembrane system, cytoplasm, and cytoskeletal structures

In immunofluorescence studies, wild-type CDC42EP3 shows a filamentous appearance, while Cdc42-binding defective mutants (Cdc42EP3-IS) display diffuse cytosolic localization .

What are the optimal experimental conditions for using CDC42EP3 antibodies in Western blot assays?

For optimal Western blot results with CDC42EP3 antibodies:

• Sample preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Load 20-40 μg of total protein per lane

• Running conditions:

  • 10-12% SDS-PAGE gels are recommended

  • Include positive control lysates (293T, K562, NIH/3T3, or rat heart tissue)

• Transfer and detection:

  • Transfer to PVDF membranes (preferred over nitrocellulose)

  • Blocking: 5% non-fat milk in TBST (1 hour at room temperature)

  • Primary antibody dilution: 1:500-1:2000 in blocking buffer

  • Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000)

  • Development: ECL detection system

• Expected results:

  • Primary band: ~37 kDa (though calculated MW is 27-28 kDa)

  • Be prepared for potential multiple bands if different modified forms exist

How should CDC42EP3 antibodies be utilized in immunohistochemistry of cancer tissues?

For optimal immunohistochemical detection of CDC42EP3 in cancer tissues:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Deparaffinize and rehydrate using standard protocols

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative option: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave)

• Staining protocol:

  • Blocking: 3% H₂O₂ followed by serum block

  • Primary antibody: Dilute 1:20-1:200 in blocking buffer

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

  • Detection: HRP-polymer system and DAB chromogen

• Analysis considerations:

  • Evaluate expression patterns across tumor and stromal compartments

  • CDC42EP3 expression correlates with pathological grading in gliomas

  • Different expression patterns may be observed in different cancers (upregulated in glioma and colorectal cancer, downregulated in ovarian cancer)

What protocols are recommended for CDC42EP3 antibody use in immunofluorescence for cytoskeletal studies?

For immunofluorescence studies examining CDC42EP3's role in cytoskeletal regulation:

• Cell preparation:

  • Culture cells on glass coverslips or chamber slides

  • Fix with 4% paraformaldehyde (10 minutes, room temperature)

  • Permeabilize with 0.2% Triton X-100 (5 minutes)

• Staining protocol:

  • Blocking: 3% BSA in PBS (1 hour, room temperature)

  • Primary antibody: Anti-CDC42EP3 (overnight at 4°C)

  • Co-staining markers:

    • F-actin: Phalloidin conjugates (Alexa Fluor 568/647)

    • Septin: Anti-SEPT2 antibodies

    • Focal adhesions: Anti-paxillin or anti-vinculin antibodies

• Visualization strategy:

  • Use super-resolution microscopy for detailed cytoskeletal structure analysis

  • Confocal microscopy for co-localization studies

  • Examine CDC42EP3 localization at the interface between F-actin fibers and SEPT2 filaments

• Expected patterns:

  • Wild-type CDC42EP3: Filamentous appearance

  • Cdc42-binding defective mutant (Cdc42EP3-IS): Diffuse cytosolic localization

How can CDC42EP3 antibodies be used to investigate its role in cancer progression mechanisms?

CDC42EP3 has different roles across cancer types, making antibody-based detection critical for mechanistic studies:

• Tumor tissue expression analysis:

  • Use IHC to correlate CDC42EP3 levels with pathological grades

  • In gliomas: CDC42EP3 overexpression positively correlates with higher pathological grade and recurrence

  • In ovarian cancer: CDC42EP3 downregulation correlates with poor prognosis

• Mechanistic pathway investigations:

  • For glioma: Examine CDC42EP3-CCND1 axis via c-Myc-mediated transcription

  • For colorectal cancer: Investigate EMT markers and proliferation pathways

  • For CAF studies: Analyze stress fiber formation and focal adhesion development

• Experimental approaches:

  • Knockdown studies: Use CDC42EP3 antibodies to confirm protein depletion after shRNA/siRNA treatment

  • Immunoprecipitation: Identify binding partners in different cancer contexts

  • ChIP assays: Investigate transcriptional regulation mechanisms

• Functional readouts:

  • Cell proliferation: EdU incorporation assays with CDC42EP3 antibody co-staining

  • Migration/invasion: Correlate CDC42EP3 expression with cell motility

  • Apoptosis: Measure relationship between CDC42EP3 levels and apoptotic markers

What experimental approaches can resolve contradictory findings about CDC42EP3's role in different cancers?

The literature reports context-dependent roles for CDC42EP3 across cancer types. To address these contradictions:

• Cell-type specific analysis:

  • Use CDC42EP3 antibodies with cell-type markers in multiplexed IHC/IF

  • Compare expression between tumor cells, CAFs, and other stromal components

  • Quantify subcellular localization patterns across different contexts

• Functional validation experiments:

  • Perform rescue experiments with wild-type vs. mutant CDC42EP3

  • Assess CDC42-dependent vs. CDC42-independent functions

  • Compare effects in different genetic backgrounds

• Signaling context exploration:

  • Analyze post-translational modifications using phospho-specific antibodies

  • Investigate CDC42EP3 interaction with different GTPases across cancer types

  • Examine m⁶A RNA modification impacts on CDC42EP3 expression in ovarian cancer

• Systematic comparison approach:

  Cancer Type	CDC42EP3 Expression	Downstream Effectors	Experimental Validation Methods
  Glioma	Upregulated	CCND1 via c-Myc	shRNA knockdown, xenograft models
  Colorectal	Upregulated	EMT pathways	Cell proliferation, migration, apoptosis assays
  Ovarian	Downregulated	Immune regulation	qPCR, western blot, bioinformatics analysis

How can CDC42EP3 antibodies help elucidate its interaction with the cytoskeleton and septin network?

To investigate CDC42EP3's complex role in cytoskeletal regulation:

• Co-immunoprecipitation studies:

  • Use CDC42EP3 antibodies to pull down protein complexes

  • Identify interaction with F-actin, septins, and other cytoskeletal proteins

  • Compare wild-type vs. mutant (Cdc42EP3-IS) binding partners

• Advanced microscopy approaches:

  • Super-resolution microscopy to visualize CDC42EP3 at the F-actin/septin interface

  • Live-cell imaging with fluorescently tagged proteins

  • FRET/FLIM analysis to measure direct protein interactions

• Functional cytoskeletal studies:

  • Stress fiber formation in CAFs following CDC42EP3 manipulation

  • Focal adhesion dynamics using paxillin/vinculin co-staining

  • Contractility assays (collagen gel contraction) with CDC42EP3 antibody validation

• Mechanotransduction investigations:

  • Study CDC42EP3's role in mechanical signal transduction

  • Analyze septin network and CDC42EP3 co-localization under different mechanical stimuli

  • Examine CDC42EP3's contribution to CAF activation in response to mechanical forces

Why might CDC42EP3 antibodies show inconsistent molecular weight detection in Western blots?

The discrepancy between calculated (27-28 kDa) and observed (37 kDa) molecular weights for CDC42EP3 can be explained by several factors:

• Post-translational modifications:

  • Phosphorylation events can significantly increase apparent molecular weight

  • SUMOylation or other modifications may alter migration patterns

  • Different cell types may produce differently modified forms

• Technical considerations:

  • Gel percentage affects migration (8-10% gels may show different patterns than 12-15% gels)

  • Buffer systems and running conditions influence apparent molecular weight

  • Sample preparation methods can affect protein denaturation

• Isoform detection:

  • Alternative splicing produces multiple transcript variants

  • Different antibodies may recognize different epitopes or isoforms

  • Some antibodies may detect specific modified forms preferentially

• Validation approach:

  • Use positive control lysates (293T, K562, NIH/3T3, rat heart)

  • Include CDC42EP3-knockdown samples as negative controls

  • Consider using multiple antibodies recognizing different epitopes for verification

What are the optimal fixation and antigen retrieval protocols for CDC42EP3 immunohistochemistry in different tissue types?

Optimizing CDC42EP3 detection across tissue types requires careful consideration of fixation and antigen retrieval:

• Fixation considerations:

  • FFPE tissues: 10% neutral buffered formalin (24-48 hours)

  • Frozen sections: 4% paraformaldehyde (10-15 minutes)

  • Over-fixation can mask epitopes; under-fixation can compromise tissue morphology

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval methods:

    • Pressure cooker: 125°C for 3 minutes, then 90°C for 10 minutes

    • Microwave: 95°C for 20 minutes

    • Water bath: 95-98°C for 20-30 minutes

• Tissue-specific considerations:

  Tissue Type	Recommended Fixation	Optimal Antigen Retrieval	Special Considerations
  Brain/Glioma	10% NBF, 24-48h	TE buffer pH 9.0	Higher background in normal brain requires careful titration
  Colorectal	10% NBF, 24h	Citrate buffer pH 6.0	Mucin can cause non-specific binding
  Ovarian	10% NBF, 24h	TE buffer pH 9.0	Compare with normal ovarian epithelium
  Prostate	10% NBF, 24h	TE buffer pH 9.0	Validated in human prostate cancer tissue

• Control tissues:

  • Include known positive tissues (prostate cancer has been validated)

  • Use CDC42EP3-knockdown tissue models as negative controls

  • Consider normal-tumor paired samples for expression comparison

How can non-specific binding be minimized when using CDC42EP3 antibodies in complex tissue samples?

To minimize non-specific binding and optimize signal-to-noise ratio:

• Antibody optimization:

  • Perform titration experiments (1:20 to 1:200 for IHC)

  • Test different incubation times and temperatures

  • Consider using monoclonal antibodies for higher specificity in complex tissues

• Blocking optimization:

  • Test different blocking agents (normal serum, BSA, casein)

  • Extend blocking time for tissues with high background (1-2 hours)

  • Include protein-based blockers with detergents (0.1-0.3% Triton X-100)

• Technical strategies:

  • Add diluent washes between antibody incubations

  • Use biotin-free detection systems to avoid endogenous biotin

  • Perform antigen competition assays with recombinant CDC42EP3 protein

• Negative controls:

  • Include primary antibody omission controls

  • Use isotype controls (rabbit IgG at equivalent concentration)

  • Compare with CDC42EP3-knockdown tissues or cells

  • Validate staining pattern with a second antibody recognizing a different epitope

How should researchers interpret CDC42EP3 expression patterns in the tumor microenvironment?

CDC42EP3 expression in the tumor microenvironment requires nuanced interpretation:

• Cell-type specific analysis:

  • Distinguish between expression in tumor cells versus stromal compartments

  • In cancer-associated fibroblasts (CAFs): CDC42EP3 regulates cytoskeletal remodeling and promotes tumor-supporting phenotypes

  • In tumor cells: Function varies by cancer type (pro-tumorigenic in glioma/colorectal, potentially tumor-suppressive in ovarian cancer)

• Spatial considerations:

  • Examine expression at tumor invasion fronts versus tumor core

  • Note co-localization with matrix remodeling markers

  • Consider relationship to hypoxic regions or vascular structures

• Prognostic implications:

  • In gliomas: Higher CDC42EP3 correlates with higher pathological grade and recurrence risk

  • In ovarian cancer: Lower CDC42EP3 expression associates with poor prognosis

  • Consider expression in relation to patient outcomes and treatment response

• Functional interpretation framework:

  Compartment	High CDC42EP3 Expression	Low CDC42EP3 Expression
  CAFs	Enhanced ECM remodeling, increased contractility, promoted tumor invasion	Reduced matrix support, decreased invasion support
  Glioma cells	Increased cell proliferation and migration, reduced apoptosis	Restricted growth and migration, enhanced apoptosis
  Ovarian cancer	Potentially better prognosis, immune regulation	Associated with poorer outcomes

What experimental designs best elucidate CDC42EP3's role in mechanotransduction and cancer-associated fibroblast activation?

To investigate CDC42EP3's role in mechanotransduction:

• Matrix stiffness experimental models:

  • Culture fibroblasts on substrates of varying stiffness (0.5-50 kPa)

  • Analyze CDC42EP3 expression, localization, and septin organization

  • Compare normal fibroblasts versus CAFs in mechanically diverse environments

• Force application studies:

  • Magnetic twisting cytometry with CDC42EP3 immunofluorescence

  • Stretch application systems (cyclic or static)

  • Micropattern-based techniques to control cell shape and force generation

• Genetic manipulation approaches:

  • Express wild-type vs. mutant CDC42EP3 (Cdc42EP3-IS) in fibroblasts

  • Examine subsequent force generation and mechanosensing

  • Analyze stress fiber formation, focal adhesions, and contractility

  • Investigate septin organization at actin interfaces

• Downstream readouts:

  • Collagen gel contraction assays

  • Traction force microscopy

  • YAP/TAZ nuclear localization (mechanotransduction markers)

  • Matrix remodeling (aligned collagen/fibronectin)

  • CAF marker expression (α-SMA, FAP, palladin)

How can CDC42EP3 antibodies be integrated into multi-parameter analysis of signaling networks in cancer research?

For comprehensive analysis of CDC42EP3 in cancer signaling networks:

• Multiplexed immunofluorescence approaches:

  • Combine CDC42EP3 antibodies with markers for:

    • Cytoskeletal components (F-actin, SEPT2)

    • Signaling molecules (c-Myc, CCND1)

    • Cell identity markers (cytokeratins, vimentin, α-SMA)

  • Use spectral unmixing or sequential staining methods

• Single-cell analysis integration:

  • Combine CDC42EP3 IHC with digital spatial profiling

  • Correlate CDC42EP3 expression with transcriptomic signatures

  • Analyze at single-cell resolution across tumor regions

• Pathway analysis methods:

  • Phospho-proteomic analysis following CDC42EP3 manipulation

  • Correlation with Rho-GTPase pathway activity

  • Investigation of relationships with EMT programs

  • Analysis of immune regulatory networks in ovarian cancer context

• Systems biology approaches:

  • Network analysis integrating CDC42EP3 interactome data

  • Correlation with clinical outcomes across cancer types

  • Examination of CDC42EP3 regulation by:

    • Transcription factors

    • microRNAs

    • m⁶A RNA modification (particularly in ovarian cancer)

  • Integration with CAF activation states and tumor-promoting mechanisms